Skip to main content
    A

    Adaptive Biotechnologies Corp (ADPT)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $27.87
    -1.17 (-4.03%)

    Market Cap: $4.70B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Adaptive Biotechnologies Corp (ADPT) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Adaptive Biotechnologies (ADPT) is expected to report earnings on Feb 3, 2027. In the quarter ended Sep 30, 2026, Adaptive Biotechnologies reported EPS of $0.02, above the -$0.10 estimate. It beat the EPS estimate in each of the last 12 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    87%(26/30)
    Avg Surprise
    +16.09%
    Streak
    12 Q

    Upcoming Estimates

    Reports Feb 3, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.07
    Range-$0.08 - -$0.04
    11 analysts
    Revenue Consensus
    $82.13M
    Range$76.44M - $87.15M
    10 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.10
    Range-$0.10 - -$0.10
    2 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.10+2.0%
    60d ago-$0.10+2.0%
    30d ago-$0.100.0%
    7d ago-$0.100.0%
    Current-$0.10
    Revenue Consensus
    $80.41M
    Range$77.71M - $82.80M
    7 analysts

    Next Report

    ADPT has an expected report date of Feb 3, 2027.

    ADPT Earnings Call

    The latest ADPT earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 30 quarters below that had an estimate, ADPT beat 26 and missed 4. Revenue for the quarter ended Sep 30, 2026 was $83.90M, down 10.7% from $93.97M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.02-$0.10-$0.11 - -$0.08+120.00%BeatN/A71 up, 0 downNov 4, 2026$83.90M
    Jun 30, 2026-$0.10-$0.13-$0.15 - -$0.11+23.08%BeatN/A72 up, 3 downJul 28, 2026$71.55M
    Mar 31, 2026-$0.13-$0.16-$0.20 - -$0.15+18.75%BeatN/A70 up, 1 downMay 5, 2026$70.87M
    Dec 31, 2025-$0.09-$0.18-$0.20 - -$0.17+50.00%BeatN/A71 up, 1 downFeb 5, 2026$71.68M
    Sep 30, 2025-$0.15-$0.16-$0.22 - $0.01+6.25%BeatN/A72 up, 0 downNov 5, 2025$93.97M
    Jun 30, 2025-$0.17-$0.24-$0.26 - -$0.22+29.17%BeatN/A51 up, 0 downAug 5, 2025$58.88M
    Mar 31, 2025-$0.20-$0.31-$0.34 - -$0.28+35.48%BeatN/A30 up, 4 downMay 1, 2025$52.44M
    Dec 31, 2024-$0.23-$0.24-$0.27 - -$0.21+4.17%BeatN/A45 up, 0 downFeb 11, 2025$47.46M
    Sep 30, 2024-$0.22-$0.27-$0.35 - -$0.24+18.52%BeatN/A81 up, 0 downNov 7, 2024$46.44M
    Jun 30, 2024-$0.29-$0.33-$0.37 - -$0.27+12.12%BeatN/A80 up, 0 downAug 1, 2024$43.19M
    Mar 31, 2024-$0.32-$0.34-$0.37 - -$0.31+5.88%BeatN/A70 up, 0 downMay 7, 2024$41.87M
    Dec 31, 2023-$0.30-$0.33-$0.36 - -$0.30+9.09%BeatN/A80 up, 1 downFeb 14, 2024$45.78M
    Sep 30, 2023-$0.35-$0.34-$0.37 - -$0.23-2.94%MissN/A90 up, 2 downNov 9, 2023$37.92M
    Jun 30, 2023-$0.33-$0.35-$0.38 - -$0.30+5.71%BeatN/A101 up, 0 downAug 2, 2023$48.93M
    Mar 31, 2023-$0.40-$0.37-$0.46 - -$0.29-8.11%MissN/A100 up, 0 downMay 3, 2023$37.65M
    Dec 31, 2022-$0.28-$0.35-$0.41 - -$0.30+20.00%BeatN/A100 up, 0 downFeb 14, 2023$55.20M
    Sep 30, 2022-$0.32-$0.38-$0.41 - -$0.32+15.79%BeatN/A80 up, 1 downNov 3, 2022$47.83M
    Jun 30, 2022-$0.37-$0.43-$0.50 - -$0.36+13.95%BeatN/A71 up, 0 downAug 3, 2022$43.66M
    Mar 31, 2022-$0.44-$0.45-$0.52 - -$0.40+2.22%BeatN/A60 up, 0 downMay 4, 2022$38.62M
    Dec 31, 2021-$0.43-$0.45-$0.53 - -$0.38+4.44%BeatN/A71 up, 0 downFeb 15, 2022$37.93M
    Sep 30, 2021-$0.40-$0.43-$0.45 - -$0.39+6.98%BeatN/A8N/ANov 3, 2021$39.47M
    Jun 30, 2021-$0.35-$0.41-$0.47 - -$0.37+14.63%BeatN/A7N/AAug 4, 2021$38.51M
    Mar 31, 2021-$0.29-$0.40-$0.44 - -$0.39+27.50%BeatN/A7N/AMay 5, 2021$38.44M
    Dec 31, 2020-$0.33-$0.29-$0.31 - -$0.27-13.79%MissN/A7N/AFeb 24, 2021$86.94M
    Sep 30, 2020-$0.27-$0.28-$0.31 - -$0.26+3.57%BeatN/A7N/ANov 10, 2020N/A
    Jun 30, 2020-$0.26-$0.28-$0.39 - -$0.21+7.14%BeatN/A4N/AAug 10, 2020N/A
    Mar 31, 2020-$0.25-$0.21-$0.22 - -$0.20-19.05%MissN/A4N/AMay 12, 2020$11.44M
    Dec 31, 2019-$0.17-$0.20-$0.25 - -$0.14+15.00%BeatN/A5N/AFeb 26, 2020$36.07M
    Sep 30, 2019-$0.11-$0.22-$0.64 - -$0.15+50.00%BeatN/A6N/ANov 12, 2019$26.06M
    Jun 30, 2019-$0.13-$0.14-$0.16 - -$0.11+7.14%BeatN/A6N/AAug 13, 2019$10.27M
    Mar 31, 2019-$0.18N/AN/AN/AN/AN/AN/AN/AJun 27, 2019$12.67M
    Last 31 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.61, after -$1.06 the year before. It was -$0.59 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.61N/A
    Dec 31, 2024-$1.06N/A
    Dec 31, 2023-$1.38N/A
    Dec 31, 2022-$1.41N/A
    Dec 31, 2021-$1.47N/A
    Dec 31, 2020-$1.11N/A
    Dec 31, 2019-$0.59N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,000 words across 11 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,03811
    2026Q1Mar 31, 20265,94013
    2025Q4Dec 31, 20255,32512
    2025Q3Sep 30, 20257,14812
    2025Q2Jun 30, 20256,52810
    2025Q1Mar 31, 20256,70613
    2024Q4Dec 31, 20246,31414
    2024Q3Sep 30, 20244,97411

    2026Q3 Earnings Call

    Opening remarks

    Karina Calzadilla Head of Investor Relations Thank you, Daniel, and good afternoon, everyone. I would like to welcome you to Adaptive Biotechnologies Third Quarter 2026 Earnings Conference Call. Earlier today, we issued a press release reporting Adaptive's financial results for the third quarter of '26. The press release is available at www.adaptivebiotech.com. We are conducting a live webcast of this call and will be referencing a slide presentation that has been posted to the Investors section of our corporate website. During the call, management will make projections and other forward-looking statements within the meaning of federal securities laws regarding future events and the future financial performance of the company. These statements reflect management's current perspective of the business as of today. Actual results may differ materially from today's forward-looking statements, depending on a number of factors, which are set forth in our public filings with the SEC and listed in this presentation. In addition, non-GAAP financial measures will be discussed during the call, and a reconciliation from non-GAAP to GAAP metrics can be found in our earnings release. Joining the call today are Chad Robins, our CEO and Co-Founder, and Kyle Piskel, our Chief Financial Officer. Additional members from management will be available for Q&A. With that, I'll turn the call over to Chad. Chad?

    Chad Robins CEO and Co-Founder Thanks, Karina. Good afternoon, and thank you for joining us on our third-quarter earnings call. Q3 was a breakthrough quarter for Adaptive. We achieved profitability at the total company level ahead of expectations, while continuing to deliver rapid MRD growth. MRD revenue, excluding milestones, increased 44% year-over-year, driven by clinical testing volume and pharma sequencing revenue. We achieved total company gross margin of 76%, generated $8 million in free cash flow, and ended the quarter with approximately $386 million in total cash. These results demonstrate that we have been building toward a business that combines rapid growth with a strong financial profile. Achieving profitability reflects years of disciplined execution, thoughtful capital allocation, and targeted investment in sustainable growth. The opportunity ahead continues to expand. Updated guidelines and a new definition of cure in multiple myeloma strengthened the clinical foundation for clonoSEQ. With clinical volumes and pharma revenue exceeding our expectations, we are again raising our full-year 2026 MRD revenue guidance. On the Immune Medicine front, we are working closely with Morgan Stanley to advance the separation process and remain on track to announce the path forward by year-end. This quarter, the business also earned a milestone payment from Pfizer following the successful delivery of rheumatoid arthritis data under our agreement, an important accomplishment for the team. Let's take a closer look at the MRD clinical business on Slide 4.

    Frequently Asked Questions About ADPT

    When is Adaptive Biotechnologies's next earnings date?

    Adaptive Biotechnologies's next earnings report is expected for Feb 3, 2027.

    Did ADPT beat earnings estimates last quarter?

    Yes. Adaptive Biotechnologies reported EPS of $0.02 for the quarter ended Sep 30, 2026, above the -$0.10 estimate, a 120.00% surprise.

    What EPS do analysts expect from ADPT next quarter?

    The consensus EPS estimate for Adaptive Biotechnologies for the quarter ending Dec 31, 2026 is -$0.07 from 11 analysts, with estimates from -$0.08 to -$0.04.

    How often does ADPT beat earnings estimates?

    Adaptive Biotechnologies beat the EPS estimate in each of the last 12 quarters, with an average surprise of +27.71%.